Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pier Mannuccio Mannucci

Showing results (1-10 of 465) with videos related to

Pageof 47
Sort By:
Expert Opinion on Investigational Drugs|January 29, 2020
Benefits and limitations of extended plasma half-life factor VIII products in hemophilia APier Mannuccio Mannucci
European Journal of Internal Medicine|March 19, 2013
Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and CharybdisPier Mannuccio Mannucci
European Journal of Internal Medicine|May 21, 2013
Thrombotic microangiopathies: the past as prologuePier Mannuccio Mannucci
Blood Transfusion = Trasfusione Del Sangue|December 25, 2008
Prophylaxis in congenital coagulation disorders: past, present and futurePier Mannuccio Mannucci
Pathophysiology of Haemostasis and Thrombosis|July 21, 2006
Thrombotic thromboytopenic purpura: another example of immunomediated thrombosisPier Mannuccio Mannucci
Internal and Emergency Medicine|December 20, 2011
Clinical governance: many fancies, very few factsPier Mannuccio Mannucci
Thrombosis and Haemostasis|October 3, 2014
Half-life extension technologies for haemostatic agentsPier Mannuccio Mannucci
Haematologica|April 1, 2022
Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2Pier Mannuccio Mannucci
European Journal of Preventive Cardiology|November 6, 2023
Health and the environment: messages for the cardiologistPier Mannuccio Mannucci
Haematologica|May 2, 2023
Recombinant FVIII: the milestone of modern hemophilia treatmentPier Mannuccio Mannucci
Pageof 47

Showing results (1-10 of 465) with videos related to

Sort By:
Pageof 47
Expert Opinion on Investigational Drugs|January 29, 2020
Benefits and limitations of extended plasma half-life factor VIII products in hemophilia APier Mannuccio Mannucci
European Journal of Internal Medicine|March 19, 2013
Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and CharybdisPier Mannuccio Mannucci
European Journal of Internal Medicine|May 21, 2013
Thrombotic microangiopathies: the past as prologuePier Mannuccio Mannucci
Blood Transfusion = Trasfusione Del Sangue|December 25, 2008
Prophylaxis in congenital coagulation disorders: past, present and futurePier Mannuccio Mannucci
Pathophysiology of Haemostasis and Thrombosis|July 21, 2006
Thrombotic thromboytopenic purpura: another example of immunomediated thrombosisPier Mannuccio Mannucci
Internal and Emergency Medicine|December 20, 2011
Clinical governance: many fancies, very few factsPier Mannuccio Mannucci
Thrombosis and Haemostasis|October 3, 2014
Half-life extension technologies for haemostatic agentsPier Mannuccio Mannucci
Haematologica|April 1, 2022
Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2Pier Mannuccio Mannucci
European Journal of Preventive Cardiology|November 6, 2023
Health and the environment: messages for the cardiologistPier Mannuccio Mannucci
Haematologica|May 2, 2023
Recombinant FVIII: the milestone of modern hemophilia treatmentPier Mannuccio Mannucci
Pageof 47